CA2013966C - Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins - Google Patents

Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins Download PDF

Info

Publication number
CA2013966C
CA2013966C CA002013966A CA2013966A CA2013966C CA 2013966 C CA2013966 C CA 2013966C CA 002013966 A CA002013966 A CA 002013966A CA 2013966 A CA2013966 A CA 2013966A CA 2013966 C CA2013966 C CA 2013966C
Authority
CA
Canada
Prior art keywords
mucin
tumour
antigen
composition
adenocarcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002013966A
Other languages
English (en)
French (fr)
Other versions
CA2013966A1 (en
Inventor
Peter Y. S. Fung
Michael B. Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncothyreon Canada Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of CA2013966A1 publication Critical patent/CA2013966A1/en
Application granted granted Critical
Publication of CA2013966C publication Critical patent/CA2013966C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002013966A 1989-04-05 1990-04-05 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins Expired - Lifetime CA2013966C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33321989A 1989-04-05 1989-04-05
US07/333,219 1989-04-05

Publications (2)

Publication Number Publication Date
CA2013966A1 CA2013966A1 (en) 1990-10-05
CA2013966C true CA2013966C (en) 2000-03-07

Family

ID=23301851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002013966A Expired - Lifetime CA2013966C (en) 1989-04-05 1990-04-05 Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins

Country Status (5)

Country Link
EP (1) EP0466813A4 (ja)
JP (1) JP2984366B2 (ja)
AU (1) AU633561B2 (ja)
CA (1) CA2013966C (ja)
WO (1) WO1990011764A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
NL9300846A (nl) * 1993-05-14 1994-12-01 Friesland Frico Domo Coop Werkwijze voor het screenen van voedingsprodukten op voedingsallergeniteit.
JPH11507633A (ja) * 1995-06-07 1999-07-06 トーマス・ジェファーソン・ユニバーシティ ハプテン修飾された腫瘍細胞抽出物及び癌を治療又はスクリーニングするための方法
ES2485316T3 (es) 2005-09-01 2014-08-13 Celgene Corporation Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
CN115920035A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 一种药物制剂及其在治疗肝癌中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687761A (en) * 1985-05-09 1987-08-18 Yaguang Liu Pharmaceutical composition for increasing immunity and decreasing side effects of anticancer chemotherapy
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
US4971795A (en) * 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype

Also Published As

Publication number Publication date
WO1990011764A1 (en) 1990-10-18
JP2984366B2 (ja) 1999-11-29
CA2013966A1 (en) 1990-10-05
AU5434790A (en) 1990-11-05
AU633561B2 (en) 1993-02-04
EP0466813A4 (en) 1992-07-15
JPH07500565A (ja) 1995-01-19
EP0466813A1 (en) 1992-01-22

Similar Documents

Publication Publication Date Title
Fung et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate
Livingston et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
EP0932411B1 (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
McCaffery et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
TWI611810B (zh) 具有較高碳水化合物抗原密度之疫苗及其醫藥組成合物
O'Boyle et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
EP1940461B1 (en) Concurrent chemotherapy and immunotherapy
Ragupathi et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
AU745555B2 (en) Fucosyl GM1-KLH conjugate vaccine against small cell lung cancer
US5500215A (en) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
US5660834A (en) Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
Motomura et al. HLA-A2 and-A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice
US6582697B2 (en) Enhancement of the cellular immune response
CA2013966C (en) Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
Ravindranath et al. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside
Ravindranath et al. Role of gangliosides in active immunotherapy with melanoma vaccine
US5792455A (en) Anti-idiotypic antibody vaccines
AU7435887A (en) Vaccine for stimulating or enhancing production of antibodies directed against gm2
James et al. Antitumor antibodies and immunoglobulin class and subclass levels in Corynebacterium parvum-treated mice
JP2001508764A (ja) 免疫原性ｔｌｐ組成物
JP2003524583A (ja) 黒色腫患者における肺転移に対して抗腫瘍応答を誘導する方法
Yoshida et al. Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells
Ben-Hur et al. Soluble low-molecular-mass tumor-associated proteins promote the suppression of mammary tumors by cyclophosphamide
Phillips et al. Antibody Response to Tumour Xenografts in Mice treated with Antilymphocyte Serum
RAVINDRANATH DONALD L. MORTON AND

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202